Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2005 1
2007 1
2009 2
2013 1
2015 2
2016 1
2017 1
2018 1
2019 3
2021 3
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Local delivery of optimized nanobodies targeting the PD-1/PD-L1 axis with a self-amplifying RNA viral vector induces potent antitumor responses.
Silva-Pilipich N, Blanco E, Lozano T, Martisova E, Igea A, Herrador-Cañete G, Ballesteros-Briones MC, Gorraiz M, Sarrión P, González-Sapienza G, Lasarte JJ, Vanrell L, Smerdou C. Silva-Pilipich N, et al. Among authors: gorraiz m. Cancer Lett. 2023 May 1;561:216139. doi: 10.1016/j.canlet.2023.216139. Epub 2023 Mar 29. Cancer Lett. 2023. PMID: 37001752 Free article.
Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells.
Martín-Otal C, Lasarte-Cia A, Serrano D, Casares N, Conde E, Navarro F, Sánchez-Moreno I, Gorraiz M, Sarrión P, Calvo A, De Andrea CE, Echeveste J, Vilas A, Rodriguez-Madoz JR, San Miguel J, Prosper F, Hervas-Stubbs S, Lasarte JJ, Lozano T. Martín-Otal C, et al. Among authors: gorraiz m. J Immunother Cancer. 2022 Aug;10(8):e004479. doi: 10.1136/jitc-2021-004479. J Immunother Cancer. 2022. PMID: 35918123 Free PMC article.
TCR-induced FOXP3 expression by CD8+ T cells impairs their anti-tumor activity.
Lozano T, Conde E, Martín-Otal C, Navarro F, Lasarte-Cia A, Nasrallah R, Alignani D, Gorraiz M, Sarobe P, Romero JP, Vilas A, Roychoudhuri R, Hervás-Stubbs S, Casares N, Lasarte JJ. Lozano T, et al. Among authors: gorraiz m. Cancer Lett. 2022 Mar 1;528:45-58. doi: 10.1016/j.canlet.2021.12.030. Epub 2021 Dec 29. Cancer Lett. 2022. PMID: 34973390
Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy.
Navarro F, Casares N, Martín-Otal C, Lasarte-Cía A, Gorraiz M, Sarrión P, Llopiz D, Reparaz D, Varo N, Rodriguez-Madoz JR, Prosper F, Hervás-Stubbs S, Lozano T, Lasarte JJ. Navarro F, et al. Among authors: gorraiz m. Oncoimmunology. 2022 May 1;11(1):2070337. doi: 10.1080/2162402X.2022.2070337. eCollection 2022. Oncoimmunology. 2022. PMID: 35529677 Free PMC article.
Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation.
Lozano T, Villanueva L, Durántez M, Gorraiz M, Ruiz M, Belsúe V, Riezu-Boj JI, Hervás-Stubbs S, Oyarzábal J, Bandukwala H, Lourenço AR, Coffer PJ, Sarobe P, Prieto J, Casares N, Lasarte JJ. Lozano T, et al. Among authors: gorraiz m. J Immunol. 2015 Oct 1;195(7):3180-9. doi: 10.4049/jimmunol.1402997. Epub 2015 Aug 31. J Immunol. 2015. PMID: 26324768
Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses.
Ballesteros-Briones MC, Martisova E, Casales E, Silva-Pilipich N, Buñuales M, Galindo J, Mancheño U, Gorraiz M, Lasarte JJ, Kochan G, Escors D, Sanchez-Paulete AR, Melero I, Prieto J, Hernandez-Alcoceba R, Hervas-Stubbs S, Smerdou C. Ballesteros-Briones MC, et al. Among authors: gorraiz m. Mol Ther. 2019 Nov 6;27(11):1892-1905. doi: 10.1016/j.ymthe.2019.09.016. Epub 2019 Sep 16. Mol Ther. 2019. PMID: 31563534 Free PMC article.
20 results